Amyotrophic lateral sclerosis (ALS) is a disorder that leads to progressive muscle weakness and loss of muscle control due to affectation of the motor neurons. Increasing evidence points to defects in the nuclear envelope, which leads to disease progression.

Shanghai Institute of Materia Medica of the Chinese Academy of Sciences has described sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain.

Arigenx Therapeutics Co. Ltd. has divulged substituted pyrimidine hydrazide compounds acting as aryl hydrocarbon receptor (AhR) antagonists reported to be useful for the treatment of cancer.

Daiichi Sankyo Co. Ltd. and Kyoto Pharmaceutical Industries Ltd. have identified Kelch-like ECH-associated protein 1 (Keap1)/Nrf2 interaction inhibitors reported to be useful for the treatment of acute lung injury, chronic kidney disease, autism, Alzheimer's disease, dry eye, heart failure, psoriasis and Sjögren's syndrome, among others.

Erasca Inc. has synthesized tricyclic pyridones and pyrimidones acting as GTPase KRAS (G12C mutant) inhibitors reported to be useful for the treatment of cancer.

Astrazeneca AB has disclosed bicyclic heteroaromatic compounds acting as transcriptional enhancer factor (TEAD) and TEAD-4 inhibitors reported to be useful for the treatment of cancer.

Saniona AB has initiated the candidate selection phase with a proprietary subtype selective frontrunner molecule from its Kv7 lead optimization program for epilepsy.